Abstract: Embodiments of the presently disclosed technology provide a synergistic combination of a conjugated open-shell donor-acceptor polymer with a carbon-based compound (e.g., reduced graphene oxide) to produce a composite electrode material which demonstrates state-of-the-art capacitance and potential window, with excellent kinetics and cycle life. The conjugated open-shell donor-acceptor polymer may comprise a plurality of alternating electron-rich monomers (i.e., donors) and electron-deficient monomers (i.e., acceptors) bonded together via a conjugated backbone. The conjugated backbone may comprise a connection of n-orbitals of the plurality of monomers in alternating single and double bonds that facilitates unpaired electron delocalization—thereby stabilizing charge for the polymer. The carbon-based compound of the composite electrode material may provide porous, conductive scaffolds for the composite electrode material, resulting in electrodes scalable to microns-thick films with fast kinetics.

Abstract: A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.

Abstract: Provided herein are dyes, dye-sensitized solar cells, and sequential series multijunction dye-sensitized solar cell devices. The dyes include an electron deficient acceptor moiety, a medium electron density ?-bridge moiety, and an electron rich donor moiety comprising a biaryl, a substituted biaryl, or an R1, R2, R3 substituted phenyl where each of R1, R2, and R3 independently comprises H, aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, OR4, N(R5)2, or a combination thereof; each R4 independently comprises H, alkyl, aryl, alkyl substituted aryl, alkoxy substituted aryl, or a combination thereof; and each R5 independently comprises aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, or a combination thereof. The solar cells include a glass substrate, a dye-sensitized active layer, and a redox shuttle.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Embodiments of the presently-disclosed subject matter include methods and systems for measuring a level of a neurotransmitter in a subject. Embodiments of the present methods comprise displaying a fixation point, a reward target, and a non-reward target, and measuring one or more saccade movement parameters for reward saccades and non-reward saccades. The saccade movement parameters can include velocity, amplitude, reaction time, or a combination thereof. The present methods can further include determining a reward modulation of the subject, the reward modulation being equal to a difference between the reward and the non-reward values for a respective saccade movement parameter. Some embodiments further include identifying the subject as including a deficiency of the neurotransmitter if there is a statistically measurable difference between the reward modulation of the subject and a reference reward modulation and/or if the non-reward and the reward saccade movement parameters are statistically equivalent.

Abstract: A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.

Abstract: Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.

Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.

Abstract: Provided herein are dyes, dye-sensitized solar cells, and sequential series multijunction dye-sensitized solar cell devices. The dyes include an electron deficient acceptor moiety, a medium electron density ?-bridge moiety, and an electron rich donor moiety comprising a biaryl, a substituted biaryl, or an R1, R2, R3 substituted phenyl where each of R1, R2, and R3 independently comprises H, aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, OR4, N(R5)2, or a combination thereof; each R4 independently comprises H, alkyl, aryl, alkyl substituted aryl, alkoxy substituted aryl, or a combination thereof; and each R5 independently comprises aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, or a combination thereof. The solar cells include a glass substrate, a dye-sensitized active layer, and a redox shuttle.

Abstract: A method for administration of citrulline for the treatment of sickle cell disease and other complications of sickle cell disease thereof.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.

Abstract: A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.

Abstract: ?9-Tetrahydrocannabinol (?9-THC or THC) and cannabidiol (CBD) are major constituents of the Cannabis plant that have pharmacological properties with potential therapeutic value. This invention is directed to processes for large scale isolation of these two and other cannabinoids from the Cannabis sativa plant. This is accomplished through the discovery that protected amino acid esters of the cannabinoids are easier to separate using normal phase silica column chromatography. Mild base hydrolysis of the esters regenerates the free cannabinoids in a purified form. The invention is also applicable to the isolation of other cannabinoids from Cannabis extracts.

Abstract: Disclosed are N-heterocyclic carbene (NHC) and 4-pyridinol-derived pincer ligands and metal complexes containing these ligands. These compounds can be used to photocatalyticaly reduce CO2 to CO.

Abstract: Provided herein are a symmetrical pincer metal and bimetallic complexes. The symmetrical pincer metal complex includes a structure according to Formula I: wherein M is a metal; each N and N? is independently nitrogen or carbon; Z is selected from the group consisting of CH, C, and N; n is 0-3; each L is independently a neutral or charged ligand; and each R is independently an alkyl, Nx, CH2TMS. The symmetrical bimetallic complex includes a structure according to Formula II: wherein M is a metal; each N and N? is independently nitrogen or carbon; Z is selected from the group consisting of CH, C, and N; n is 0-3; each L is independently a neutral or charged ligand; and wherein each R is independently an alkyl, Nx, CH2TMS. Also provided herein is a method of catalyzing a reaction including administering one or more of the compounds disclosed herein.

Abstract: Natural products were screened for their insect repellent activity, and carrot seed essential oil gave very high activity in biting repellent/deterrent bioassays. Analysis of the oil revealed the presence of 47 compounds, mainly mono- and sesqui-terpenes. The sesquiterpene, carotol, constituted more than 75% w/w of the oil. In the initial screening, the essential oil gave high biting deterrent activity and high repellent activity comparable to DEET against both Aedes aegypti and Anophies quadrimaculatus species of mosquitoes. The active fraction mainly comprises pure carotol. The essential oil and the pure compound have a potential to be developed and used as effective repellent against mosquitoes.